Synthesis and Antiproliferative Activity of Imidazole and Imidazoline Analogs for Melanoma

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2008 May 15

PMID 18477505

Citations 12

Authors

Jianjun Chen

Zhao Wang

Yan Lu

James T Dalton

Duane D Miller

Wei Li

Affiliations

Soon will be listed here.

Abstract

We have previously reported substituted 2-aryl-thiazolidine-4-carboxylic acid amides as potent and selective antiproliferative agents for melanoma. To understand the importance of the thiazolidine ring and to reduce potential complications associated with the two chiral centers, we designed and synthesized sets of new analogs by modifying this ring. These new analogs were tested in two melanoma cell lines and fibroblast cells (negative controls). Compared with the older analogs containing the thiazolidine ring, these new analogs have lower potency in general, but some of these analogs still have very good selectivity. These structure-activity studies indicated that the thiazolidine ring is very critical for the activity for these series of compounds.

Citing Articles

Various synthesis and biological evaluation of some tri -tetra-substituted imidazoles derivatives: A review.

Hamdi A, Daoudi W, Aaddouz M, Azzouzi M, Amhamdi H, Elyoussfi A Heliyon. 2024; 10(10):e31253.

PMID: 38803909 PMC: 11128531. DOI: 10.1016/j.heliyon.2024.e31253.

Influence of Steric Effect on the Pseudo-Multicomponent Synthesis of -Aroylmethyl-4-Arylimidazoles.

Elejalde-Cadena N, Garcia-Olave M, Figueroa D, Vidossich P, Miscione G, Portilla J Molecules. 2022; 27(4).

PMID: 35208948 PMC: 8874432. DOI: 10.3390/molecules27041165.

Imidazole as a Promising Medicinal Scaffold: Current Status and Future Direction.

Alghamdi S, Suliman R, Almutairi K, Kahtani K, Aljatli D Drug Des Devel Ther. 2021; 15:3289-3312.

PMID: 34354342 PMC: 8329171. DOI: 10.2147/DDDT.S307113.

Synthesis and potential antineoplastic activity of dehydroabietylamine imidazole derivatives.

Zhao F, Lu W, Su F, Xu L, Jiang D, Sun X Medchemcomm. 2019; 9(12):2091-2099.

PMID: 30746067 PMC: 6336084. DOI: 10.1039/c8md00487k.

Imidazoles as potential anticancer agents.

Ali I, Lone M, Aboul-Enein H Medchemcomm. 2018; 8(9):1742-1773.

PMID: 30108886 PMC: 6084102. DOI: 10.1039/c7md00067g.

References

Bergeron R, Wiegand J, Weimar W, Vinson J, Bussenius J, Yao G . Desazadesmethyldesferrithiocin analogues as orally effective iron chelators. J Med Chem. 1999; 42(1):95-108. DOI: 10.1021/jm980340j. View

Barth A, Wanek L, Morton D . Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995; 181(3):193-201. View

Anderson C, Buzaid A, Legha S . Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park). 1995; 9(11):1149-58; discussion 1163-4, 1167-8. View

Eisen T, Ahmad T, Flaherty K, Gore M, Kaye S, Marais R . Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006; 95(5):581-6. PMC: 2360687. DOI: 10.1038/sj.bjc.6603291. View

Anderson W, Bhattacharjee D, Houston D . Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole. J Med Chem. 1989; 32(1):119-27. DOI: 10.1021/jm00121a023. View

CALCINARI R, Case N, Guerrato A, Milanino R, Passarella E, Perchinunno M . Synthesis and antiinflammatory activity of 2,2'-diaminobiphenyl derivatives. J Med Chem. 1981; 24(5):632-4. DOI: 10.1021/jm00137a029. View

Larkin J, Hughes S, Beirne D, Patel P, Gibbens I, Bate S . A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer. 2006; 96(1):44-8. PMC: 2360201. DOI: 10.1038/sj.bjc.6603503. View

Gray-Schopfer V, Wellbrock C, Marais R . Melanoma biology and new targeted therapy. Nature. 2007; 445(7130):851-7. DOI: 10.1038/nature05661. View

Serrone L, Zeuli M, Sega F, Cognetti F . Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res. 2000; 19(1):21-34. View

10.

Li W, Lu Y, Wang Z, Dalton J, Miller D . Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorg Med Chem Lett. 2007; 17(15):4113-7. DOI: 10.1016/j.bmcl.2007.05.059. View

11.

Gogas H, Kirkwood J, Sondak V . Chemotherapy for metastatic melanoma: time for a change?. Cancer. 2007; 109(3):455-64. DOI: 10.1002/cncr.22427. View

12.

Ranson M, Hersey P, Thompson D, Beith J, McArthur G, Haydon A . Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol. 2007; 25(18):2540-5. DOI: 10.1200/JCO.2007.10.8217. View

13.

Dothager R, Putt K, Allen B, Leslie B, Nesterenko V, Hergenrother P . Synthesis and identification of small molecules that potently induce apoptosis in melanoma cells through G1 cell cycle arrest. J Am Chem Soc. 2005; 127(24):8686-96. DOI: 10.1021/ja042913p. View

14.

Koon H, Atkins M . Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance. Expert Rev Anticancer Ther. 2006; 7(1):79-88. DOI: 10.1586/14737140.7.1.79. View

15.

Li W, Wang Z, Gududuru V, Zbytek B, Slominski A, Dalton J . Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Res. 2007; 27(2):883-8. View

16.

Gududuru V, Hurh E, Dalton J, Miller D . Discovery of 2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer. J Med Chem. 2005; 48(7):2584-8. DOI: 10.1021/jm049208b. View

17.

Young A, Marsden J, Goodman A, Burton A, Dunn J . Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol). 2002; 13(6):458-65. DOI: 10.1053/clon.2001.9314. View

18.

Sawada Y, Kayakiri H, Abe Y, Mizutani T, Inamura N, Asano M . A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile. J Med Chem. 2004; 47(10):2667-77. DOI: 10.1021/jm030326t. View

19.

HSU F, Hamada A, Booher M, Fuder H, Patil P, Miller D . Optically active derivatives of imidazolines. alpha-Adrenergic blocking properties. J Med Chem. 1980; 23(11):1232-5. DOI: 10.1021/jm00185a017. View

20.

Atallah E, Flaherty L . Treatment of metastatic malignant melanoma. Curr Treat Options Oncol. 2005; 6(3):185-93. DOI: 10.1007/s11864-005-0002-5. View